NCT02129777View on ClinicalTrials.gov

Efficacy and Safety of Namilumab (MT203) for Plaque Psoriasis

PHASE2CompletedINTERVENTIONAL

Enrollment

122

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

September 30, 2015

Study Completion Date

February 29, 2016

Conditions

Plaque Psoriasis

Interventions

DRUG

Namilumab

Namilumab subcutaneous injection

DRUG

Placebo

Placebo subcutaneous injection

Trial Locations (10)

Unknown

Calgary

Edmonton

Barrie

Hamilton

Markham

North Bay

Peterborough

Richmond Hill

Waterloo

Québec

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Takeda

INDUSTRY